Esophageal Squamous Cell Cancer

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Esophageal Squamous Cell Cancer is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

6/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Unknown status9 · 56%

Completed5 · 31%

Terminated1 · 6%

Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

Active, not recruiting·SShanghai Chest Hospital·Phase 2·NCT05621707·50 enrolled

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03416244·66 enrolled

Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

Completed·—·Phase 1·NCT01384708·70 enrolled

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Completed·SSamsung Medical Center·Phase 2·NCT01469598·24 enrolled

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Completed·—·Phase 2·NCT02976896·43 enrolled

Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.

Completed·SSun Yat-sen University·Phase 2·NCT02606916·42 enrolled

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer

Terminated·AAIO-Studien-gGmbH·Phase 3·NCT01627379·300 enrolled

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Unknown status·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT03224221·189 enrolled

SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04797507·33 enrolled

Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial

Unknown status·PPeking University·Phase 2·NCT01051765·60 enrolled

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·N/A·NCT04654403·337 enrolled

Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT05561699·66 enrolled

Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

Unknown status·PPeking University·Phase 2·NCT01336049·70 enrolled

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05322499·80 enrolled

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03603756·45 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)